摘要
目的探讨大剂量阿糖胞苷治疗急性髓细胞白血病的临床疗效。方法将30例急性髓细胞白血病患者随机分为治疗组和对照组各15例,治疗组采用常规化疗联用大剂量阿糖胞苷强化治疗,对照组仅给予常规化疗,比较两组患者治疗后1、3、5年的无病生存率。结果治疗组1、3、5年的无病生存率显著优于对照组,两组比较,差异具有统计学意义(P<0.05)。结论大剂量阿糖胞苷治疗急性髓细胞白血病的临床疗效显著,能够有效延长患者生命,提高患者生存质量,降低并发症的发生率,值得临床推广应用。
Objective To explore Cytarabine large dose treatment of acute myelocytic leukemia clinical curative effect.Methods The acute myelocytic leukemia 30 patients were randomly divided into treatment group and control group the 15 cases,the treatment group with the conventional chemotherapy combined high-dose Cytarabine strengthening treatment group,only to conventional chemotherapy,compared between the two groups after treatment in patients with 1,3,5 years of leukemia-free surial.Results The treatment group 1,3,5 years of leukemia-free surial is significantly better than control group,two groups of comparisons,a statistically significant difference（P0.05）.Conclusion Large dose Cytarabine treatment acute myelocytic leukemia clinical curative effect is distinct,and it can effectively prolong patient life,improve the survival quality and reduce the incidence of complications,it is worth clinical application.
出处
《中国医药指南》
2012年第36期45-45,59,共2页
Guide of China Medicine
